These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 29683766

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M, Tumban E, Dziduszko A, Ozbun MA, Peabody DS, Chackerian B.
    Vaccine; 2014 Jul 23; 32(34):4267-74. PubMed ID: 24962748
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S, Spagnoli G, Bulli L, Balz K, Yang F, Odenwald C, Seitz H, Mariz FC, Bolchi A, Ottonello S, Müller M.
    J Virol; 2018 Feb 15; 92(4):. PubMed ID: 29212932
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R.
    Vaccine; 2007 Mar 01; 25(11):2001-10. PubMed ID: 17239496
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE, Wui SR, Park SA, Lee NG, Kim KS, Cho YJ, Kim HJ, Kim HJ.
    Vaccine; 2012 Jun 13; 30(28):4127-34. PubMed ID: 22561312
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
    Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R.
    J Invest Dermatol; 2013 Dec 13; 133(12):2706-2713. PubMed ID: 23752042
    [Abstract] [Full Text] [Related]

  • 17. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A, Shirbaghaee Z, Agi E, Davoudi N.
    Protein Expr Purif; 2015 Dec 13; 116():7-11. PubMed ID: 26304732
    [Abstract] [Full Text] [Related]

  • 18. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y, Wei M, Wang D, Li Z, Xie M, Pan H, Wu T, Zhang J, Li S, Xia N.
    Vaccine; 2017 Aug 16; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [Abstract] [Full Text] [Related]

  • 19. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.
    Virol J; 2015 Sep 11; 12():140. PubMed ID: 26362430
    [Abstract] [Full Text] [Related]

  • 20. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
    Hanumantha Rao N, Baji Babu P, Rajendra L, Sriraman R, Pang YY, Schiller JT, Srinivasan VA.
    Vaccine; 2011 Oct 06; 29(43):7326-34. PubMed ID: 21803095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.